What are the differences between Vyvanse (lisdexamfetamine) and Adderall (mixed amphetamine salts)?

Key Differences Between Vyvanse and Adderall

Vyvanse (lisdexamfetamine) is a prodrug that requires enzymatic conversion in red blood cells to release active d-amphetamine, providing a smoother, longer-lasting effect with lower abuse potential, while Adderall (mixed amphetamine salts) delivers immediate active amphetamine with faster onset but requires multiple daily doses and carries higher abuse risk.

Pharmacological Mechanism

Vyvanse (Lisdexamfetamine)

• Prodrug design: Therapeutically inactive until converted 1
• Conversion site: Hydrolyzed primarily in red blood cells to d-amphetamine and L-lysine 1
• Not metabolized by liver enzymes: Bypasses cytochrome P450 system 1
• Predictable pharmacokinetics: Low inter-subject (<25%) and intra-subject (<8%) variability 1

Adderall (Mixed Amphetamine Salts)

• Immediate active form: Contains 75% dextroamphetamine and 25% levoamphetamine salts
• Direct mechanism: Immediately blocks dopamine/norepinephrine reuptake and increases monoamine release
• Multiple formulations: Available as immediate-release (IR) requiring 2-3 daily doses or extended-release (XR) for once-daily dosing

Duration and Timing of Effect

Vyvanse

• Time to peak effect: 3.5-4.4 hours post-dose 1
• Duration: 10-13 hours of symptom control
• Onset: Gradual, smoother rise in amphetamine levels
• Half-life: d-amphetamine elimination half-life 10-11.3 hours in adults 1
• Once-daily dosing: Single morning dose provides all-day coverage 2

Adderall

• Immediate-release: Peak effect 1-2 hours, duration 4-6 hours, requires 2-3 daily doses
• Extended-release: Bimodal release with initial peak at 1-2 hours and second peak at 4-6 hours, duration 8-10 hours
• Faster onset: More rapid symptom relief but also more abrupt wearing off

Clinical Efficacy Comparison

Both medications demonstrate equivalent efficacy for ADHD core symptoms, but Vyvanse shows advantages in specific clinical measures 3:

• ADHD symptom reduction: Equivalent response rates (~80%) in head-to-head trials 3
• Clinical Global Impression: Vyvanse demonstrated significantly greater improvements on CGI-Severity scores 3
• Executive function: Vyvanse showed superior effects on selected BRIEF (Behavior Rating Inventory of Executive Function) subscales 3
• "Very much improved" ratings: 32% with Vyvanse vs 16% with Adderall IR in pediatric studies 4

Important caveat: The research comparing these medications is limited, and individual response varies considerably. The studies showing Vyvanse superiority used immediate-release Adderall requiring three-times-daily dosing 3, which may disadvantage Adderall due to adherence issues in real-world practice.

Abuse Liability

Vyvanse - Lower Abuse Potential

• Prodrug barrier: Cannot be activated by crushing, snorting, or injecting 5
• Gradual conversion: Slow, controlled release of active d-amphetamine limits euphoric "rush" 6, 5
• Abuse liability studies: Significantly lower "drug liking" scores compared to equivalent doses of immediate-release d-amphetamine 1, 6
• Schedule II controlled substance: Still has abuse potential but reduced compared to immediate amphetamines 1

Adderall - Higher Abuse Risk

• Immediate active form: Can be crushed and insufflated or injected for rapid high
• Faster peak levels: More pronounced euphoric effects
• Multiple daily doses: More opportunities for diversion and misuse
• Schedule II controlled substance: High potential for abuse and dependence

Dosing and Administration

Vyvanse

• Starting dose: 30 mg once daily (5 mg in preschool children 4-5 years) 7
• Therapeutic range: 30-70 mg once daily 1
• Maximum dose: 70 mg/day (standard); 50 mg in severe renal impairment; 30 mg in ESRD 1
• Food effects: Minimal impact on absorption; food delays peak by ~1 hour but doesn't affect total exposure 1
• Formulations: Capsules and chewable tablets with equivalent bioavailability 1

Adderall

• Immediate-release: Starting 5-10 mg 2-3 times daily; maximum 40-60 mg/day divided
• Extended-release: Starting 10-20 mg once daily; maximum 30-40 mg/day
• Titration: More flexible dose adjustments possible with IR formulation
• Food effects: Variable depending on formulation

Side Effect Profile

Both medications share similar adverse effects as amphetamine-class stimulants 2:

Common to Both

• Decreased appetite (33% with Vyvanse in pediatric studies) 7
• Insomnia
• Dry mouth
• Increased heart rate and blood pressure
• Headache
• Irritability

Practical Differences

• Vyvanse: Smoother pharmacokinetic profile may reduce rebound effects when medication wears off 6
• Adderall IR: More pronounced peaks and troughs can cause more noticeable rebound symptoms
• Growth suppression: Both require monitoring in children; effects similar 1

Guideline Recommendations

Current guidelines position both medications as first-line stimulant options, with methylphenidate typically tried first 2:

• US guidelines: Both lisdexamfetamine and Adderall approved as first-line therapies 2
• European guidelines: Lisdexamfetamine often positioned as second-line after methylphenidate failure 2
• Sequential approach: If methylphenidate fails, lisdexamfetamine should be preferred as the next option over non-stimulants 2

Clinical Decision-Making Algorithm

Choose Vyvanse when:

• Once-daily dosing is priority for adherence
• Patient has history of substance use disorder (lower diversion risk)
• Smoother, longer duration of effect needed (school + homework + evening activities)
• Previous issues with Adderall rebound effects
• Concern about medication diversion in household

Choose Adderall when:

• Immediate-release flexibility needed for dose timing
• Shorter duration of effect desired (e.g., medication-free evenings)
• Cost is prohibitive (generic Adderall less expensive)
• Patient has severe renal impairment requiring lower maximum doses
• Faster onset of action needed

Common Pitfalls to Avoid:

• Don't assume Vyvanse's prodrug design means it's "safer" - both are Schedule II controlled substances with significant abuse potential 1
• Don't overlook adherence issues with multiple-daily-dosing Adderall IR in real-world practice 2
• Don't exceed licensed doses without clear clinical justification - unlicensed doses may not provide additional benefit but increase adverse events 8
• Don't forget that individual response varies considerably; some patients respond better to one formulation despite theoretical advantages of another 2

Special Populations

Renal Impairment

• Vyvanse: Maximum 50 mg/day in severe impairment (GFR 15-30); 30 mg/day in ESRD 1
• Adderall: No specific renal dosing adjustments in labeling, but caution advised

Pediatric Considerations

• Preschool (4-5 years): Vyvanse starting dose 5 mg with careful titration 7
• School-age (6-12 years): Both effective; Vyvanse may have adherence advantage with once-daily dosing
• Adolescents: Consider diversion risk with either medication in school settings

Adults

• Both effective with similar efficacy profiles 3
• Adherence typically better with once-daily Vyvanse 2
• Dose escalation beyond licensed doses (>70 mg Vyvanse, >30 mg Adderall XR) shows minimal additional benefit with increased adverse events 8